This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Busulphan

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Busulphan is an alkylating drug now used almost exclusively to treat chronic myeloid leukaemia; it is also used to treat polycythaemia rubra vera (1,2,3)

For chronic myeloid leukaemia it is given as either a daily dose or as pulsed dose every 4-6 weeks.

In polycythaemia rubra vera, an oral dose of 4-6mg daily effectively reduces the haematocrit in combination with venesection. It is a second-line drug due to the severity of its side-effects.

  • study evidence has revealed no association between leukemic transformation and hydroxyurea or busulphan use if used in the treatment of polycythaemia (3)

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.